A Comprehensive Review of the Current and Future Role of the Microbiome in Pancreatic Ductal Adenocarcinoma

Cancers

Kayani Kayani¹  Charles J. Rayner¹  Tarak Chouari¹  José I. Jiménez²  Elisa Giovannetti³  Jonathan Krell⁴  Timothy A. Rockall⁵  Nabeel Merali⁵  Adam E. Frampton⁵  Kate Relph⁶  Izhar Bagwan⁶  Hardev Pandha⁶  Tony Dhillon⁶  Nicola E. Annels⁶ 

[1] Department of Hepato-Pancreato-Biliary (HPB) Surgery, Royal Surrey County Hospital, Egerton Road, Guildford GU2 7XX, UK;Department of Life Sciences, South Kensington Campus, Imperial College London, London SW7 2AZ, UK;Department of Medical Oncology, VU University Medical Center, Cancer Center Amsterdam, 1081 HV Amsterdam, The Netherlands;Division of Cancer, Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital Campus, London W12 0NN, UK;Minimal Access Therapy Training Unit (MATTU), Leggett Building, University of Surrey, Daphne Jackson Road, Guildford GU2 7WG, UK;Targeted Cancer Therapy Unit, Department of Clinical and Experimental Medicine, Faculty of Health and Medical Science, University of Surrey, Guildford GU2 7WG, UK;

关键词: pancreatic ductal adenocarcinoma;    microbiome;    mycobiome;    FMT;    immunology;    biomarkers;   

DOI  :  10.3390/cancers14041020

来源: DOAJ

【 摘 要 】

Pancreatic ductal adenocarcinoma (PDAC) is expected to become the second most common cause of cancer death in the USA by 2030, yet progress continues to lag behind that of other cancers, with only 9% of patients surviving beyond 5 years. Long-term survivorship of PDAC and improving survival has, until recently, escaped our understanding. One recent frontier in the cancer field is the microbiome. The microbiome collectively refers to the extensive community of bacteria and fungi that colonise us. It is estimated that there is one to ten prokaryotic cells for each human somatic cell, yet, the significance of this community in health and disease has, until recently, been overlooked. This review examines the role of the microbiome in PDAC and how it may alter survival outcomes. We evaluate the possibility of employing microbiomic signatures as biomarkers of PDAC. Ultimately this review analyses whether the microbiome may be amenable to targeting and consequently altering the natural history of PDAC.

【 授权许可】

Unknown